Effect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 14-Day Repeated-Dose Administration of Thiamphenicol (RUX 122) in Healthy Subjects
  • Phase

    Phase 1
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    urfamicin ...
  • Study Participants

The purpose of this study is to determine if two-weeks of dosing with thiamphenicol is safe and is able to change the levels of certain pre-specified biomarkers in nervous tissue taken from the nasal passages.
Thiamphenicol has been proposed to increase the levels of the excitatory amino acid transporter 2 (EAAT2) in the nervous tissue. This study evaluated the ability of two weeks of treatment with thiamphenicol to increase EAAT2 in a nasal biopsy as a surrogate of brain nervous tissue.
Study Started
Jul 31
Primary Completion
Sep 30
Study Completion
Apr 30
Last Update
Mar 25

Drug Thiamphenicol

750 and 1500 mg/day;tablets

  • Other names: Thiamphenicol, Urfamycine (trade name in Belgium)

Drug Placebo

Matched tablets without active ingredient

Placebo Placebo Comparator


Thiamphenicol Active Comparator

Active comparator


Inclusion Criteria:

normal volunteers

Exclusion Criteria:

less than 18 years
older than 55 years
No Results Posted